ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.77
-1.09%
US Tech 100
20,891.60
0.00%
S&P 500
6,040.53
-0.50%
US Dollar vs CAD
1.47173
0.02%
Bitcoin
95,343.59
-2.41%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Verve Therapeutics Inc (VERV) Share Price

Verve Therapeutics Inc

Verve Therapeutics Inc (VERV)

Verbund Ag
Verbund Ag
Verbund Ag
Verbund Ag
7.61
0.00
(0.00%)
Closed February 03 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
7.61
Bid
7.33
Ask
7.75
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
644.292M
Previous Close
7.61
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
84,663,840
Dividend Yield
-
PE Ratio
-3.22
Earnings Per Share (EPS)
-2.36
Revenue
11.76M
Net Profit
-200.07M

About Verve Therapeutics Inc

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.vervetx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Verve Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VERV. The last closing price for Verve Therapeutics was US$7.61. Over the last year, Verve Therapeutics shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Verve Therapeutics currently has 84,663,840 shares outstanding. The market capitalization of Verve Therapeutics is US$644.29 million. Verve Therapeutics has a price to earnings ratio (PE ratio) of -3.22.

Ask ADVFN Intelligence (AI)

VERV Latest News

More News

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 31, 2025 NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

January 31 2025
PR Newswire (US)

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar...

January 29 2025
GlobeNewswire Inc.

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301...

January 13 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

January 10 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 10 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 10 2025
Edgar (US Regulatory)

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar...

January 08 2025
GlobeNewswire Inc.

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December...

January 03 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

December 04 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

VERV - Frequently Asked Questions (FAQ)

What is the current Verve Therapeutics share price?
The current share price of Verve Therapeutics is US$ 7.61
How many Verve Therapeutics shares are in issue?
Verve Therapeutics has 84,663,840 shares in issue
What is the market cap of Verve Therapeutics?
The market capitalisation of Verve Therapeutics is USD 644.29M
What is the 1 year trading range for Verve Therapeutics share price?
Verve Therapeutics has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Verve Therapeutics?
The price to earnings ratio of Verve Therapeutics is -3.22
What is the cash to sales ratio of Verve Therapeutics?
The cash to sales ratio of Verve Therapeutics is 54.79
What is the reporting currency for Verve Therapeutics?
Verve Therapeutics reports financial results in USD
What is the latest annual turnover for Verve Therapeutics?
The latest annual turnover of Verve Therapeutics is USD 11.76M
What is the latest annual profit for Verve Therapeutics?
The latest annual profit of Verve Therapeutics is USD -200.07M
What is the registered address of Verve Therapeutics?
The registered address for Verve Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Verve Therapeutics website address?
The website address for Verve Therapeutics is www.vervetx.com
Which industry sector does Verve Therapeutics operate in?
Verve Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
US$ 16.92
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.4033
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.88
(0.00%)
0
AACGATA Creativity Global
US$ 0.79325
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 16.92
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.4033
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.88
(0.00%)
0
AACGATA Creativity Global
US$ 0.79325
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 16.92
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.4033
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.88
(0.00%)
0
AACGATA Creativity Global
US$ 0.79325
(0.00%)
0

VERV Discussion

View Posts
Monksdream Monksdream 6 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 6 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 6 months ago
VERV 10Q due AUGUST5
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 8 months ago
VERV more new lows up ahead
👍️0
Monksdream Monksdream 8 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 9 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 9 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 9 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 10 months ago
VERV new 52 lo
👍️0
Firestorm22 Firestorm22 10 months ago
uh oh
👍️0
Monksdream Monksdream 10 months ago
VERV over $10
👍️0
fink fink 12 months ago
Looking for an entry now
👍️0
Terpi Terpi 1 year ago
Could see another nice move here is the 50 day holds into close.
👍️0
Monksdream Monksdream 1 year ago
VERV morning rally
👍️0
TheFinalCD TheFinalCD 2 years ago
https://cathiesark.com/
👍️0
crudeoil24 crudeoil24 3 years ago
VERV IS A GREAT $$$$$ OPPORTUNITY.
👍️0
crudeoil24 crudeoil24 3 years ago
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
👍️0
crudeoil24 crudeoil24 3 years ago
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
👍️0

Your Recent History

NASDAQ
VERV
Verve Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads